Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 213

1.

Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.

Wardell SE, Yllanes AP, Chao CA, Bae Y, Andreano KJ, Desautels TK, Heetderks KA, Blitzer JT, Norris JD, McDonnell DP.

Breast Cancer Res Treat. 2019 Nov 16. doi: 10.1007/s10549-019-05498-0. [Epub ahead of print]

PMID:
31734822
2.

Different packing motifs mediated by weak inter-actions and polymorphism in the crystal structures of five 2-(benzyl-idene)benzosuberone derivatives.

Seaman LS, da Costa CF, de Souza MVN, Wardell SMSV, Wardell JL, Harrison WTA.

Acta Crystallogr E Crystallogr Commun. 2019 Oct 29;75(Pt 11):1741-1747. doi: 10.1107/S2056989019014245. eCollection 2019 Nov 1.

3.

The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.

Cocce KJ, Jasper JS, Desautels TK, Everett L, Wardell S, Westerling T, Baldi R, Wright TM, Tavares K, Yllanes A, Bae Y, Blitzer JT, Logsdon C, Rakiec DP, Ruddy DA, Jiang T, Broadwater G, Hyslop T, Hall A, Laine M, Phung L, Greene GL, Martin LA, Pancholi S, Dowsett M, Detre S, Marks JR, Crawford GE, Brown M, Norris JD, Chang CY, McDonnell DP.

Cell Rep. 2019 Oct 22;29(4):889-903.e10. doi: 10.1016/j.celrep.2019.09.032.

4.

A large-scale whole-genome comparison shows that experimental evolution in response to antibiotics predicts changes in naturally evolved clinical Pseudomonas aeruginosa.

Wardell SJT, Rehman A, Martin LW, Winstanley C, Patrick WM, Lamont IL.

Antimicrob Agents Chemother. 2019 Sep 30. pii: AAC.01619-19. doi: 10.1128/AAC.01619-19. [Epub ahead of print]

PMID:
31570397
5.

Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.

Wardell SE, Yllanes AP, Chao CA, Bae Y, Andreano KJ, Desautels TK, Heetderks KA, Blitzer JT, Norris JD, McDonnell DP.

Breast Cancer Res Treat. 2019 Nov 14. doi: 10.1007/s10549-019-05454-y. [Epub ahead of print] Erratum in: Breast Cancer Res Treat. 2019 Nov 16;:.

PMID:
31562570
6.

Genomic and phenotypic comparison of environmental and patient-derived isolates of Pseudomonas aeruginosa suggest that antimicrobial resistance is rare within the environment.

Ramsay KA, Wardell SJT, Patrick WM, Brockway B, Reid DW, Winstanley C, Bell SC, Lamont IL.

J Med Microbiol. 2019 Nov;68(11):1591-1595. doi: 10.1099/jmm.0.001085.

PMID:
31553303
7.

Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models.

Manzari MT, Anderson GR, Lin KH, Soderquist RS, Çakir M, Zhang M, Moore CE, Skelton RN, Fèvre M, Li X, Bellucci JJ, Wardell SE, Costa SA, Wood KC, Chilkoti A.

Sci Adv. 2019 Sep 4;5(9):eaaw9162. doi: 10.1126/sciadv.aaw9162. eCollection 2019 Sep.

8.

Targeting mutant estrogen receptors.

Wardell SE, Norris JD, McDonnell DP.

Elife. 2019 Jan 16;8. pii: e44181. doi: 10.7554/eLife.44181.

9.

Racemic mefloquinium chloro-difluoro-acetate: crystal structure and Hirshfeld surface analysis.

Wardell JL, Wardell SMSV, Jotani MM, Tiekink ERT.

Acta Crystallogr E Crystallogr Commun. 2018 Jun 5;74(Pt 7):895-900. doi: 10.1107/S2056989018007703. eCollection 2018 Jul 1.

10.

Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer.

Puyang X, Furman C, Zheng GZ, Wu ZJ, Banka D, Aithal K, Agoulnik S, Bolduc DM, Buonamici S, Caleb B, Das S, Eckley S, Fekkes P, Hao MH, Hart A, Houtman R, Irwin S, Joshi JJ, Karr C, Kim A, Kumar N, Kumar P, Kuznetsov G, Lai WG, Larsen N, Mackenzie C, Martin LA, Melchers D, Moriarty A, Nguyen TV, Norris J, O'Shea M, Pancholi S, Prajapati S, Rajagopalan S, Reynolds DJ, Rimkunas V, Rioux N, Ribas R, Siu A, Sivakumar S, Subramanian V, Thomas M, Vaillancourt FH, Wang J, Wardell S, Wick MJ, Yao S, Yu L, Warmuth M, Smith PG, Zhu P, Korpal M.

Cancer Discov. 2018 Sep;8(9):1176-1193. doi: 10.1158/2159-8290.CD-17-1229. Epub 2018 Jul 10.

11.

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.

Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C.

Clin Cancer Res. 2018 Sep 15;24(18):4416-4428. doi: 10.1158/1078-0432.CCR-17-3649. Epub 2018 May 30.

12.

Different mol-ecular conformations in the crystal structures of three 5-nitro-imidazolyl derivatives.

Osorio LFB, Carvalho SA, da Silva EF, Fraga CAM, Wardell SMSV, Milne BF, Wardell JL, Harrison WTA.

Acta Crystallogr E Crystallogr Commun. 2018 Feb 23;74(Pt 3):380-384. doi: 10.1107/S2056989018002876. eCollection 2018 Mar 1.

13.

Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.

Tavera RJ, Forget MA, Kim YU, Sakellariou-Thompson D, Creasy CA, Bhatta A, Fulbright OJ, Ramachandran R, Thorsen ST, Flores E, Wahl A, Gonzalez AM, Toth C, Wardell S, Mansaray R, Radvanyi LG, Gombos DS, Patel SP, Hwu P, Amaria RN, Bernatchez C, Haymaker C.

J Immunother. 2018 Nov/Dec;41(9):399-405. doi: 10.1097/CJI.0000000000000230.

14.

Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors.

Anderson GR, Wardell SE, Cakir M, Yip C, Ahn YR, Ali M, Yllanes AP, Chao CA, McDonnell DP, Wood KC.

Nat Commun. 2018 Apr 26;9(1):1677. doi: 10.1038/s41467-018-04033-x.

15.

Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.

McLeod AB, Stice JP, Wardell SE, Alley HM, Chang CY, McDonnell DP.

Prostate. 2018 Mar;78(4):266-277. doi: 10.1002/pros.23467. Epub 2017 Dec 15.

PMID:
29243324
16.

The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells.

Baek AE, Yu YA, He S, Wardell SE, Chang CY, Kwon S, Pillai RV, McDowell HB, Thompson JW, Dubois LG, Sullivan PM, Kemper JK, Gunn MD, McDonnell DP, Nelson ER.

Nat Commun. 2017 Oct 11;8(1):864. doi: 10.1038/s41467-017-00910-z.

17.

A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product.

Liberti MV, Dai Z, Wardell SE, Baccile JA, Liu X, Gao X, Baldi R, Mehrmohamadi M, Johnson MO, Madhukar NS, Shestov AA, Chio IIC, Elemento O, Rathmell JC, Schroeder FC, McDonnell DP, Locasale JW.

Cell Metab. 2017 Oct 3;26(4):648-659.e8. doi: 10.1016/j.cmet.2017.08.017. Epub 2017 Sep 14.

18.

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes.

Forget MA, Tavera RJ, Haymaker C, Ramachandran R, Malu S, Zhang M, Wardell S, Fulbright OJ, Toth CL, Gonzalez AM, Thorsen ST, Flores E, Wahl A, Peng W, Amaria RN, Hwu P, Bernatchez C.

Front Immunol. 2017 Aug 2;8:908. doi: 10.3389/fimmu.2017.00908. eCollection 2017.

19.

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.

Anderson GR, Winter PS, Lin KH, Nussbaum DP, Cakir M, Stein EM, Soderquist RS, Crawford L, Leeds JC, Newcomb R, Stepp P, Yip C, Wardell SE, Tingley JP, Ali M, Xu M, Ryan M, McCall SJ, McRee AJ, Counter CM, Der CJ, Wood KC.

Cell Rep. 2017 Jul 25;20(4):999-1015. doi: 10.1016/j.celrep.2017.07.006.

20.

Evaluation of 1,3-benzoxathiol-2-one Derivatives as Potential Antifungal Agents.

Terra L, de L Chazin E, de S Sanches P, Saito M, de Souza MVN, Gomes CRB, Wardell JL, Wardell SMSV, Sathler PC, Silva GCC, Lione VO, Kalil M, Joffily A, Castro HC, Vasconcelos TRA.

Med Chem. 2018;14(3):304-310. doi: 10.2174/1573406413666170704095113.

PMID:
28676004
21.

Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling.

Tang X, Ding CK, Wu J, Sjol J, Wardell S, Spasojevic I, George D, McDonnell DP, Hsu DS, Chang JT, Chi JT.

Oncogene. 2017 Jul 27;36(30):4379. doi: 10.1038/onc.2017.192. Epub 2017 Jun 12.

PMID:
28604749
22.

The 1:1 co-crystal of 2-bromo-naphthalene-1,4-dione and 1,8-di-hydroxy-anthracene-9,10-dione: crystal structure and Hirshfeld surface analysis.

Tonin MDL, Garden SJ, Jotani MM, Wardell SMSV, Wardell JL, Tiekink ERT.

Acta Crystallogr E Crystallogr Commun. 2017 Apr 21;73(Pt 5):738-745. doi: 10.1107/S2056989017005667. eCollection 2017 May 1.

23.

Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.

Norris JD, Ellison SJ, Baker JG, Stagg DB, Wardell SE, Park S, Alley HM, Baldi RM, Yllanes A, Andreano KJ, Stice JP, Lawrence SA, Eisner JR, Price DK, Moore WR, Figg WD, McDonnell DP.

J Clin Invest. 2017 Jun 1;127(6):2326-2338. doi: 10.1172/JCI87328. Epub 2017 May 2.

24.

CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC.

Stice JP, Wardell SE, Norris JD, Yllanes AP, Alley HM, Haney VO, White HS, Safi R, Winter PS, Cocce KJ, Kishton RJ, Lawrence SA, Strum JC, McDonnell DP.

Mol Cancer Res. 2017 Jun;15(6):660-669. doi: 10.1158/1541-7786.MCR-17-0028. Epub 2017 Feb 16.

25.

Correction: Copper(ii) catalyzed synthesis of novel helical luminescent benzo[4,5]imidazo[1,2-a][1,10]phenanthrolines via an intramolecular C-H amination reaction.

da Silva RB, Teixeira RI, Wardell JL, Wardell SM, Garden SJ.

Org Biomol Chem. 2017 Jan 25;15(4):1013-1014. doi: 10.1039/c6ob90191c.

PMID:
28094393
26.

N-(2-(arylmethylimino)ethyl)-7-chloroquinolin-4-amine derivatives, synthesized by thermal and ultrasonic means, are endowed with anti-Zika virus activity.

Barbosa-Lima G, da Silveira Pinto LS, Kaiser CR, Wardell JL, De Freitas CS, Vieira YR, Marttorelli A, Cerbino Neto J, Bozza PT, Wardell SMSV, de Souza MVN, Souza TML.

Eur J Med Chem. 2017 Feb 15;127:434-441. doi: 10.1016/j.ejmech.2017.01.007. Epub 2017 Jan 6.

PMID:
28092859
27.

Copper(ii) catalyzed synthesis of novel helical luminescent benzo[4,5]imidazo[1,2-a][1,10]phenanthrolines via an intramolecular C-H amination reaction.

Borges da Silva R, Teixeira RI, Wardell JL, Wardell SM, Garden SJ.

Org Biomol Chem. 2017 Jan 25;15(4):812-826. doi: 10.1039/c6ob02508k. Erratum in: Org Biomol Chem. 2017 Jan 25;15(4):1013-1014.

PMID:
27991627
28.

PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.

Anderson GR, Wardell SE, Cakir M, Crawford L, Leeds JC, Nussbaum DP, Shankar PS, Soderquist RS, Stein EM, Tingley JP, Winter PS, Zieser-Misenheimer EK, Alley HM, Yllanes A, Haney V, Blackwell KL, McCall SJ, McDonnell DP, Wood KC.

Sci Transl Med. 2016 Dec 14;8(369):369ra175.

29.

Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling.

Tang X, Ding CK, Wu J, Sjol J, Wardell S, Spasojevic I, George D, McDonnell DP, Hsu DS, Chang JT, Chi JT.

Oncogene. 2017 Jul 27;36(30):4235-4242. doi: 10.1038/onc.2016.394. Epub 2016 Nov 21. Erratum in: Oncogene. 2017 Jun 12;:.

30.

N'-[(1E)-(5-Nitro-furan-2-yl)methyl-idene]thio-phene-2-carbohydrazide: crystal structure and Hirshfeld surface analysis.

Cardoso LN, Nogueira TC, Wardell JL, Wardell SM, de Souza MV, Jotani MM, Tiekink ER.

Acta Crystallogr E Crystallogr Commun. 2016 Jun 24;72(Pt 7):1025-31. doi: 10.1107/S2056989016009968. eCollection 2016 Jul 1.

31.

Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer.

Pollock JA, Wardell SE, Parent AA, Stagg DB, Ellison SJ, Alley HM, Chao CA, Lawrence SA, Stice JP, Spasojevic I, Baker JG, Kim SH, McDonnell DP, Katzenellenbogen JA, Norris JD.

Nat Chem Biol. 2016 Oct;12(10):795-801. doi: 10.1038/nchembio.2131. Epub 2016 Aug 8.

32.

A kryptoracemic salt: 2-{[2,8-bis-(tri-fluoro-meth-yl)quinolin-4-yl](hy-droxy)meth-yl}piperidin-1-ium (+)-3,3,3-tri-fluoro-2-meth-oxy-2-phenyl-propanoate.

Wardell JL, Wardell SM, Tiekink ER.

Acta Crystallogr E Crystallogr Commun. 2016 May 27;72(Pt 6):872-7. doi: 10.1107/S2056989016008495. eCollection 2016 Jun 1.

33.

Diagnosis of lead-induced tricuspid regurgitation.

Wardell S, Kuriachan V, Weeks SG, Belenkie I.

HeartRhythm Case Rep. 2016 Jan 12;2(2):173-177. doi: 10.1016/j.hrcr.2016.01.004. eCollection 2016 Mar. No abstract available.

34.

Synthesis and Biological Activities of Camphor Hydrazone and Imine Derivatives.

da Silva ET, da Silva Araújo A, Moraes AM, de Souza LA, Silva Lourenço MC, de Souza MV, Wardell JL, Wardell SM.

Sci Pharm. 2015 Oct 18;84(3):467-483. doi: 10.3390/scipharm84030467.

35.

Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report.

Glitza IC, Haymaker C, Bernatchez C, Vence L, Rohlfs M, Richard J, Lacey C, Mansaray R, Fulbright OJ, Ramachandran R, Toth C, Wardell S, Patel SP, Woodman SE, Hwu WJ, Radvanyi LG, Davies MA, Papadopoulos NE, Hwu P.

Cancer Immunol Res. 2015 Nov;3(11):1201-6. doi: 10.1158/2326-6066.CIR-15-0071. Epub 2015 Jul 27.

36.

Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader.

Wardell SE, Nelson ER, Chao CA, Alley HM, McDonnell DP.

Endocr Relat Cancer. 2015 Oct;22(5):713-24. doi: 10.1530/ERC-15-0287. Epub 2015 Jul 10.

37.

Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.

McDonnell DP, Wardell SE, Norris JD.

J Med Chem. 2015 Jun 25;58(12):4883-7. doi: 10.1021/acs.jmedchem.5b00760. Epub 2015 Jun 3.

38.

Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.

Wardell SE, Ellis MJ, Alley HM, Eisele K, VanArsdale T, Dann SG, Arndt KT, Primeau T, Griffin E, Shao J, Crowder R, Lai JP, Norris JD, McDonnell DP, Li S.

Clin Cancer Res. 2015 Nov 15;21(22):5121-5130. doi: 10.1158/1078-0432.CCR-15-0360. Epub 2015 May 19.

39.

Synthesis and biological evaluation of novel 6-hydroxy-benzo[d][1,3]oxathiol-2-one Schiff bases as potential anticancer agents.

Chazin Ede L, Sanches Pde S, Lindgren EB, Vellasco Júnior WT, Pinto LC, Burbano RM, Yoneda JD, Leal KZ, Gomes CR, Wardell JL, Wardell SM, Montenegro RC, Vasconcelos TR.

Molecules. 2015 Jan 27;20(2):1968-83. doi: 10.3390/molecules20021968.

40.

Systematic identification of signaling pathways with potential to confer anticancer drug resistance.

Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini DM, Wood KC.

Sci Signal. 2014 Dec 23;7(357):ra121. doi: 10.1126/scisignal.aaa1877.

41.

The association between obesity and outcomes in critically ill patients.

Wardell S, Wall A, Bryce R, Gjevre JA, Laframboise K, Reid JK.

Can Respir J. 2015 Jan-Feb;22(1):23-30. Epub 2014 Nov 6.

42.

Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.

Wright TM, Wardell SE, Jasper JS, Stice JP, Safi R, Nelson ER, McDonnell DP.

Mol Cancer Res. 2014 Dec;12(12):1829-39. doi: 10.1158/1541-7786.MCR-14-0195. Epub 2014 Aug 6.

43.

From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).

Wardell SE, Nelson ER, McDonnell DP.

Steroids. 2014 Nov;90:30-8. doi: 10.1016/j.steroids.2014.07.013. Epub 2014 Jul 30.

44.

Obesity, cholesterol metabolism, and breast cancer pathogenesis.

McDonnell DP, Park S, Goulet MT, Jasper J, Wardell SE, Chang CY, Norris JD, Guyton JR, Nelson ER.

Cancer Res. 2014 Sep 15;74(18):4976-82. doi: 10.1158/0008-5472.CAN-14-1756. Epub 2014 Jul 24.

45.

A qualitative and quantitative analysis of the New Zealand media portrayal of Down syndrome.

Wardell S, Fitzgerald RP, Legge M, Clift K.

Disabil Health J. 2014 Apr;7(2):242-50. doi: 10.1016/j.dhjo.2013.11.006. Epub 2013 Dec 12.

PMID:
24680054
46.

Anti-tuberculosis evaluation and conformational study of N-acylhydrazones containing the thiophene nucleus.

Cardoso LN, Bispo ML, Kaiser CR, Wardell JL, Wardell SM, Lourenço MC, Bezerra FA, Soares RP, Rocha MN, de Souza MV.

Arch Pharm (Weinheim). 2014 Jun;347(6):432-48. doi: 10.1002/ardp.201300417. Epub 2014 Mar 10.

PMID:
24616002
47.

3,3-Dimethyl-cis-9a,13a-diphenyl-2,3,9a,11,12,13a-hexa-hydro-1H-benzo[h][1,4]dioxino[2',3':5,6][1,4]dioxino[2,3-f]chromene.

Bernardes BO, Ferreira AB, Wardell JL, Wardell SM, Netto-Ferreira JC, Tiekink ER.

Acta Crystallogr Sect E Struct Rep Online. 2013 Aug 31;69(Pt 9):o1487-8. doi: 10.1107/S1600536813023660. eCollection 2013.

48.

Design, synthesis and biological evaluation of (E)-2-(2-arylhydrazinyl)quinoxalines, a promising and potent new class of anticancer agents.

Rodrigues FA, Bomfim Ida S, Cavalcanti BC, Pessoa Cdo Ó, Wardell JL, Wardell SM, Pinheiro AC, Kaiser CR, Nogueira TC, Low JN, Gomes LR, de Souza MV.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):934-9. doi: 10.1016/j.bmcl.2013.12.074. Epub 2013 Dec 25.

PMID:
24398294
49.

27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology.

Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, Umetani M, Geradts J, McDonnell DP.

Science. 2013 Nov 29;342(6162):1094-8. doi: 10.1126/science.1241908.

50.

Mefloquine-oxazolidine derivatives: a new class of anticancer agents.

Rodrigues FA, Bomfim Ida S, Cavalcanti BC, Pessoa C, Goncalves RS, Wardell JL, Wardell SM, de Souza MV.

Chem Biol Drug Des. 2014 Jan;83(1):126-31. doi: 10.1111/cbdd.12210. Epub 2013 Oct 5.

PMID:
23961998

Supplemental Content

Loading ...
Support Center